PE20150723A1 - Compuestos antiviricos para el vsr - Google Patents

Compuestos antiviricos para el vsr

Info

Publication number
PE20150723A1
PE20150723A1 PE2015000497A PE2015000497A PE20150723A1 PE 20150723 A1 PE20150723 A1 PE 20150723A1 PE 2015000497 A PE2015000497 A PE 2015000497A PE 2015000497 A PE2015000497 A PE 2015000497A PE 20150723 A1 PE20150723 A1 PE 20150723A1
Authority
PE
Peru
Prior art keywords
compounds
rsv
methylpropanoyl
indol
chloro
Prior art date
Application number
PE2015000497A
Other languages
English (en)
Inventor
Abdellah Tahri
Sandrine Marie Helene Vendeville
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Lili Hu
Samuel Dominique Demin
Ludwig Paul Cooymans
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of PE20150723A1 publication Critical patent/PE20150723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Referida a inhibidores de la replicacion del virus sincitial respiratorio (VSR) de formula (RI) incluyendo sus formas estereoquimicamente isomericas y sus sales o solvatos, donde R22, W, Q, V, Z, p, s y Het tienen el significado que se define en la presente solicitud. Tambien esta referida a procesos para preparar dichos compuestos, a composiciones farmaceuticas que los contienen. Son compuestos preferidos: 4-(5-cloro-2-((1-(2-hidroxi-2-metilpropanoil)-2'-oxoespiro[azetidin-3,3'-indolin]-1'-il)metil)-1H-indol-1-il)butanonitrilo, 1'-((5-cloro-1-(3-(metilsulfonil)propil)-1H-indol-2-il)-metil-1-(2-hidroxi-2-metilpropanoil)espiro[piperidin-4,3'pirrolo[2,3-c]piridin]-2'(1'H)-ona, entre otros
PE2015000497A 2012-10-16 2013-10-15 Compuestos antiviricos para el vsr PE20150723A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12188694 2012-10-16
EP13159431 2013-03-15

Publications (1)

Publication Number Publication Date
PE20150723A1 true PE20150723A1 (es) 2015-05-15

Family

ID=49385250

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000497A PE20150723A1 (es) 2012-10-16 2013-10-15 Compuestos antiviricos para el vsr

Country Status (35)

Country Link
US (1) US9617289B2 (es)
EP (1) EP2909195B1 (es)
JP (1) JP6375300B2 (es)
KR (1) KR102280918B1 (es)
CN (1) CN104903313B (es)
AR (1) AR093020A1 (es)
AU (1) AU2013334001B2 (es)
BR (1) BR112015008325B1 (es)
CA (1) CA2884491C (es)
CL (1) CL2015000925A1 (es)
CY (1) CY1119566T1 (es)
DK (1) DK2909195T3 (es)
EA (1) EA026628B1 (es)
EC (1) ECSP15014941A (es)
ES (1) ES2640446T3 (es)
HK (1) HK1210462A1 (es)
HR (1) HRP20171351T1 (es)
HU (1) HUE033476T2 (es)
IL (1) IL237857A (es)
LT (1) LT2909195T (es)
ME (1) ME02835B (es)
MX (1) MX363717B (es)
MY (1) MY172021A (es)
NZ (1) NZ705759A (es)
PE (1) PE20150723A1 (es)
PH (1) PH12015500780A1 (es)
PL (1) PL2909195T3 (es)
PT (1) PT2909195T (es)
SA (1) SA515360258B1 (es)
SG (1) SG11201503025WA (es)
SI (1) SI2909195T1 (es)
TW (1) TWI598351B (es)
UA (1) UA114531C2 (es)
WO (1) WO2014060411A1 (es)
ZA (1) ZA201502532B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI501967B (zh) * 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
DK3243826T3 (da) 2012-04-26 2020-02-03 Bristol Myers Squibb Co Imidazothiadiazol-og imidazopyrazinderivater som proteaseaktiverede receptor 4- (par4) hæmmere til behandling af blodpladeaggregation
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
US20150111868A1 (en) 2012-06-15 2015-04-23 Jansen R&D Ireland Novel 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
NZ710079A (en) 2013-01-15 2020-01-31 Incyte Holdings Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
CN105392787B (zh) * 2013-05-14 2017-11-24 豪夫迈·罗氏有限公司 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚
CA2910508A1 (en) * 2013-05-14 2014-11-20 Song Feng Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
EP3033341B1 (en) * 2013-08-12 2017-05-03 F. Hoffmann-La Roche AG Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
MX2016001858A (es) * 2013-08-15 2016-05-24 Hoffmann La Roche Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio.
AR097431A1 (es) 2013-08-23 2016-03-16 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
EP3081569B1 (en) 2013-12-10 2019-09-18 Shandong Danhong Pharmaceutical Co., Ltd. Imidazole derivative used as antiviral agent and use thereof in preparation of medicament
TWI671299B (zh) * 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
GB201417707D0 (en) 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
JP6548751B2 (ja) * 2015-06-08 2019-07-24 シャンドン ダンホン ファーマスーティカル カンパニー リミテッドＳｈａｎｄｏｎｇ Ｄａｎｈｏｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． イミダゾール誘導体及びその中間体の製造及び結晶型
RU2738232C2 (ru) 2015-07-22 2020-12-09 Энанта Фармасьютикалс, Инк. Производные бензодиазепина как ингибиторы rsv
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3380467B1 (en) 2015-11-27 2021-07-07 Janssen Sciences Ireland Unlimited Company Heterocyclic indoles for use in influenza virus infection
US20170226129A1 (en) 2016-01-15 2017-08-10 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
MX2018008803A (es) 2016-01-20 2018-11-09 Janssen Sciences Ireland Uc Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza.
WO2017137334A1 (en) * 2016-02-08 2017-08-17 F. Hoffmann-La Roche Ag Spiroindolinones as ddr1 inhibitors
RS61963B1 (sr) 2016-08-04 2021-07-30 Reviral Ltd Derivati pirimidina i njihova upotreba u lečenju ili prevenciji infekcije respiratornog sincicijalnog virusa
WO2018038668A1 (en) * 2016-08-25 2018-03-01 Medivir Ab Respiratory syncytial virus inhibitors
WO2018038667A1 (en) * 2016-08-25 2018-03-01 Medivir Ab Respiratory syncytial virus inhibitors
AU2018221820B2 (en) 2017-02-16 2023-11-02 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
GB201711704D0 (en) * 2017-07-20 2017-09-06 Reviral Ltd Pharmaceutical compounds
CN107253951B (zh) * 2017-08-01 2019-05-10 深圳百奥捷生物科技有限公司 一种嘌呤生物碱及其作为抗rsv病毒药物的应用
CN107383011B (zh) * 2017-08-01 2019-05-10 深圳百奥捷生物科技有限公司 一种分离自连翘叶黄芩的抗病毒生物碱及其制备方法
CN109369658B (zh) * 2017-08-08 2020-01-31 沈阳药科大学 一种螺[吡咯烷-3,3`-氧化吲哚]环系的合成方法
WO2019067864A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV
WO2019094903A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
MX2021002569A (es) 2018-09-06 2021-06-08 Cidara Therapeutics Inc Composiciones y metodos para el tratamiento de infecciones virales.
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11254664B2 (en) 2019-03-18 2022-02-22 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020252396A1 (en) * 2019-06-13 2020-12-17 Cidara Therapeutics, Inc. Compositions and methods for the treatment of respiratory syncytial virus
AR119765A1 (es) 2019-08-14 2022-01-12 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
WO2021050612A1 (en) * 2019-09-09 2021-03-18 Cidara Therapeutics, Inc. Compositions and methods for the treatment of respiratory syncytial virus
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US11572367B2 (en) 2019-10-04 2023-02-07 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
KR20220091465A (ko) * 2019-10-30 2022-06-30 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 3-(｛5-클로로-1-[3-(메틸설포닐)프로필]-1H-인돌-2-일｝메틸)-1-(2,2,2-트리플루오로에틸)-1,3-디히드로-2H-이미다조[4,5-c]피리딘-2-온의 합성
WO2021098732A1 (zh) * 2019-11-18 2021-05-27 江苏恩华药业股份有限公司 一种1',2'-二氢-3'h-螺[环丁烷1,4'-异喹啉]-3'-酮衍生物及其应用
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
MX2023009961A (es) 2021-02-26 2023-09-05 Enanta Pharm Inc Compuestos heterociclicos antivirales.
WO2022184606A1 (en) * 2021-03-01 2022-09-09 Janssen Sciences Ireland Unlimited Company Synthesis of rilematovir
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN117751124A (zh) * 2021-12-17 2024-03-22 南京药石科技股份有限公司 螺环氧化吲哚类化合物及其用于制备抗病毒蛋白酶抑制剂药物的用途
WO2023200441A1 (en) * 2022-04-13 2023-10-19 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
US6506738B1 (en) * 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
AR043692A1 (es) 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) * 2003-02-28 2003-04-02 Novartis Ag Organic compounds
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI527814B (zh) * 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
GB201119538D0 (en) * 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
HUE033476T2 (en) 2017-12-28
CL2015000925A1 (es) 2015-08-28
HRP20171351T1 (hr) 2017-11-03
KR20150070168A (ko) 2015-06-24
MX363717B (es) 2019-03-29
CY1119566T1 (el) 2018-03-07
JP6375300B2 (ja) 2018-08-15
AU2013334001B2 (en) 2017-07-20
BR112015008325A2 (pt) 2017-07-04
PT2909195T (pt) 2017-09-13
PL2909195T3 (pl) 2017-12-29
IL237857A (en) 2017-02-28
KR102280918B1 (ko) 2021-07-23
MX2015004787A (es) 2015-08-14
UA114531C2 (uk) 2017-06-26
WO2014060411A1 (en) 2014-04-24
CN104903313A (zh) 2015-09-09
CN104903313B (zh) 2017-12-29
SG11201503025WA (en) 2015-06-29
ZA201502532B (en) 2017-11-29
EP2909195A1 (en) 2015-08-26
EA201590748A1 (ru) 2015-07-30
ES2640446T3 (es) 2017-11-03
US20150259367A1 (en) 2015-09-17
MY172021A (en) 2019-11-12
CA2884491A1 (en) 2014-04-24
AR093020A1 (es) 2015-05-13
JP2015534966A (ja) 2015-12-07
PH12015500780B1 (en) 2015-06-15
PH12015500780A1 (en) 2015-06-15
CA2884491C (en) 2021-08-31
EA026628B1 (ru) 2017-04-28
HK1210462A1 (en) 2016-04-22
BR112015008325B1 (pt) 2022-01-25
US9617289B2 (en) 2017-04-11
NZ705759A (en) 2019-01-25
EP2909195B1 (en) 2017-06-14
ECSP15014941A (es) 2016-01-29
DK2909195T3 (en) 2017-09-25
TWI598351B (zh) 2017-09-11
LT2909195T (lt) 2017-09-25
SA515360258B1 (ar) 2016-07-16
ME02835B (me) 2018-01-20
TW201427983A (zh) 2014-07-16
SI2909195T1 (sl) 2017-10-30
AU2013334001A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
PE20150723A1 (es) Compuestos antiviricos para el vsr
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
DK3359542T3 (da) Spiro[3h-indol-3,2'-pyrrolidin]-2(1h)-on-forbindelser og derivater som mdm2-p53-inhibitorer
PH12017501140A1 (en) TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
SV2010003642A (es) Compuestos
PE20150758A1 (es) Nuevos derivados biciclicos
ECSP10010585A (es) Compuestos de 2- imido- 3- metil pirrolo pirimidinona fenilo- sustituidos como inhibidores bace- 1, composiciones, y su uso
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY39887A (es) (r)-(2-cloro-3-(trifluorometil)fenil)(1-(5-fluoropirimidin2-il)-4-metil-6,7-dihidro-1h-[1,2,3]triazolo-[4,5-c]piridin5(4h)-il)metanona como modulador del receptor p2x7
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
DOP2016000333A (es) Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida
PE20151413A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
PE20151755A1 (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos
UY29177A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CL2013001723A1 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina; metodos de preparacion; composicion farmaceutica; y el uso en el tratamiento de los trastornos mediados por la cinasa de linfoma anaplasico.
CO6491087A2 (es) Compuestos de urea que contienen heteroarilo 5,6 bicíclicos como inhibidores de quinasa
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
CL2009001884A1 (es) Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
GT201300080A (es) Proceso de elaboracion para derivados de pirimidina
CL2011002467A1 (es) Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional.
DOP2015000170A (es) Compuestos químicos
CL2016001342A1 (es) Formas cristalinas hemihidrato y anhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que las comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras.

Legal Events

Date Code Title Description
FG Grant, registration